Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Trading 01-15 14:40:14 EST

18.41

-0.18

-0.97%

High19.23	Low18.13	Vol748.47K
Open18.87	D1 Closing18.59	Amplitude5.92%
Mkt Cap576.05M	Tradable Cap288.90M	Total Shares31.29M
T/O13.88M	T/O Rate4.77%	Tradable Shares15.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":18.41,"timestamp":1768506010453,"preClose":18.59,"halted":0,"volume":748470,"delay":0,"floatShares":15692500,"shares":31289969,"eps":-2.10871,"marketStatus":"Trading","change":-0.18,"latestTime":"01-15 14:40:14 EST","open":18.8668,"high":19.23,"low":18.13,"amount":13878837.29568,"amplitude":0.059172,"askPrice":18.43,"askSize":65,"bidPrice":18.4,"bidSize":530,"shortable":3,"etf":0,"ttmEps":-2.10871,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768510800000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":18.59,"preHourTrading":{"tag":"盘前","latestPrice":18.76,"preClose":18.59,"latestTime":"09:29 EST","volume":638,"amount":11961.142973999999,"timestamp":1768487369076},"postHourTrading":{"tag":"盘后","latestPrice":18.84,"preClose":18.59,"latestTime":"19:53 EST","volume":7439,"amount":138211.5132,"timestamp":1768438433481},"volumeRatio":0.629948,"impliedVol":0.8213,"impliedVolPercentile":0.5052},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2603398425","title":"Summit Therapeutics Advances Ivonescimab Into Key Phase 3 Test in Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2603398425","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603398425?lang=en_us&edition=fundamental","pubTime":"2026-01-16 00:34","pubTimestamp":1768494855,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC ($SMMT) announced an update on their ongoing clinical study. Summit Therapeutics Steps Up in Colorectal Cancer With New Pha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-advances-ivonescimab-into-key-phase-3-test-in-metastatic-colorectal-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-advances-ivonescimab-into-key-phase-3-test-in-metastatic-colorectal-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4211","SMMF","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2603602725","title":"Avalo Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2603602725","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603602725?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:24","pubTimestamp":1768479840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2026 07:24 ET (12:24 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2603629921","title":"Alterity Therapeutics Issues 18 Million Unlisted Options Under Employee Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2603629921","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603629921?lang=en_us&edition=fundamental","pubTime":"2026-01-15 09:33","pubTimestamp":1768440782,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has issued an update. Alterity Therapeutics has notified the market of the issue of 18 million unlisted options...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-issues-18-million-unlisted-options-under-employee-scheme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-issues-18-million-unlisted-options-under-employee-scheme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2603641984","title":"Plus Therapeutics Prices Upsized $15 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2603641984","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603641984?lang=en_us&edition=fundamental","pubTime":"2026-01-15 03:49","pubTimestamp":1768420176,"startTime":"0","endTime":"0","summary":"Plus Therapeutics (PSTV) said Wednesday it priced an upsized underwritten public offering of about 39.5 million units at $0.38 each, expected to raise approximately $15 million in gross proceeds.Each ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PSTV","BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2603649203","title":"LENZ Therapeutics: Early VIZZ Launch, Targeted DTC Campaign, and Differentiated Presbyopia Profile Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2603649203","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603649203?lang=en_us&edition=fundamental","pubTime":"2026-01-15 03:16","pubTimestamp":1768418185,"startTime":"0","endTime":"0","summary":"William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on LENZ stock, giving a Buy rating on January 12. Lachlan Hanbury B...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/lenz-therapeutics-early-vizz-launch-targeted-dtc-campaign-and-differentiated-presbyopia-profile-underpin-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/lenz-therapeutics-early-vizz-launch-targeted-dtc-campaign-and-differentiated-presbyopia-profile-underpin-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2603369645","title":"Beam Therapeutics: De-Risked Late-Stage Pipeline, Clear FDA Pathways, and Strong Cash Runway Underscore Buy Rating and $80 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2603369645","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603369645?lang=en_us&edition=fundamental","pubTime":"2026-01-15 01:07","pubTimestamp":1768410469,"startTime":"0","endTime":"0","summary":"Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Beam Therapeutics. The associated price target remains the same wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/beam-therapeutics-de-risked-late-stage-pipeline-clear-fda-pathways-and-strong-cash-runway-underscore-buy-rating-and-80-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/beam-therapeutics-de-risked-late-stage-pipeline-clear-fda-pathways-and-strong-cash-runway-underscore-buy-rating-and-80-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","LENZ"],"gpt_icon":0},{"id":"2603487606","title":"Denali Therapeutics Advances New Early-Stage Alzheimer’s Drug Into Phase 1b Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603487606","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603487606?lang=en_us&edition=fundamental","pubTime":"2026-01-15 00:32","pubTimestamp":1768408321,"startTime":"0","endTime":"0","summary":"Denali Therapeutics ($DNLI) announced an update on their ongoing clinical study. Study Overview Denali Therapeutics is launching a Phase 1b study t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/denali-therapeutics-advances-new-early-stage-alzheimers-drug-into-phase-1b-testing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/denali-therapeutics-advances-new-early-stage-alzheimers-drug-into-phase-1b-testing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","BK4007","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"1181051106","title":"Stock Track | LENZ Therapeutics Soars 5.24% Intraday on Launch of \"Make It Vizzable\" Campaign with Sarah Jessica Parker","url":"https://stock-news.laohu8.com/highlight/detail?id=1181051106","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181051106?lang=en_us&edition=fundamental","pubTime":"2026-01-15 00:14","pubTimestamp":1768407260,"startTime":"0","endTime":"0","summary":"LENZ Therapeutics (LENZ) saw its stock price surge 5.24% during intraday trading following the announcement of its new consumer campaign, \"Make It Vizzable,\" featuring Sarah Jessica Parker as the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["LENZ"],"gpt_icon":0},{"id":"2603619452","title":"BRIEF-Lenz Therapeutics Launch Of “Make It Vizzable” With Sarah Jessica Parker As A Brand Ambassador","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619452","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603619452?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:37","pubTimestamp":1768397861,"startTime":"0","endTime":"0","summary":"BRIEF-Lenz Therapeutics Launch Of “Make It Vizzable” With Sarah Jessica Parker As A Brand AmbassadorJan 14 (Reuters) - Lenz Therapeutics Inc LENZ.O:LENZ THERAPEUTICS: LAUNCH OF “MAKE IT VIZZABLE” WITH","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nFWN3YF1UT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2603191796","title":"Lenz Therapeutics: Launch of “Make It Vizzable” With Sarah Jessica Parker as a Brand Ambassador","url":"https://stock-news.laohu8.com/highlight/detail?id=2603191796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603191796?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:35","pubTimestamp":1768397759,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nFWN3YF1UT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2603619013","title":"LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2603619013","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603619013?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:30","pubTimestamp":1768397400,"startTime":"0","endTime":"0","summary":"Struggling to see up close?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/14/3218622/0/en/LENZ-Therapeutics-and-Sarah-Jessica-Parker-announce-the-launch-of-Make-it-VIZZable-the-VIZZ-consumer-campaign.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2603616745","title":"Plus Therapeutics prices 39.5M units at 38c in upsized public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616745","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616745?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:17","pubTimestamp":1768396673,"startTime":"0","endTime":"0","summary":"Plus Therapeutics (PSTV) announces the pricing of its underwritten public offering of 39,473,684 units, with each unit consisting of one share of c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-prices-39-5m-units-at-38c-in-upsized-public-offering-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/plus-therapeutics-prices-39-5m-units-at-38c-in-upsized-public-offering-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSTV","BK4539","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2603616946","title":"Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616946","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616946?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:00","pubTimestamp":1768395600,"startTime":"0","endTime":"0","summary":"HOUSTON, Jan.  14, 2026  (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/14/3218538/0/en/Plus-Therapeutics-Announces-Pricing-of-Upsized-15-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","CNS","BK4007","BK4139","BK4135","PSTV"],"gpt_icon":0},{"id":"2603753618","title":"Travere Therapeutics price target lowered to $43 from $47 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2603753618","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603753618?lang=en_us&edition=fundamental","pubTime":"2026-01-14 19:51","pubTimestamp":1768391511,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Travere Therapeutics (TVTX) to $43 from $47 and keeps a Buy rating on the shares after the FDA extended its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-price-target-lowered-to-43-from-47-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-price-target-lowered-to-43-from-47-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2603269218","title":"Buy Rating Reaffirmed on Travere Therapeutics: Attractive Risk/Reward Despite FDA Delay and Near‑Term Catalyst Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2603269218","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603269218?lang=en_us&edition=fundamental","pubTime":"2026-01-14 18:36","pubTimestamp":1768387007,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Travere Therapeutics, with a price target of $48.00. Yigal N...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reaffirmed-on-travere-therapeutics-attractive-risk-reward-despite-fda-delay-and-near‑term-catalyst-reset-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reaffirmed-on-travere-therapeutics-attractive-risk-reward-despite-fda-delay-and-near‑term-catalyst-reset-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2603261839","title":"Will Dispatch Bio CAR T Solid Tumor Trial Shift CARsgen Therapeutics' (SEHK:2171) Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603261839","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603261839?lang=en_us&edition=fundamental","pubTime":"2026-01-14 18:25","pubTimestamp":1768386329,"startTime":"0","endTime":"0","summary":"In January 2026, Dispatch Bio and CARsgen Therapeutics announced a clinical collaboration in China to start a Phase 1 trial evaluating DISP-11, which combines Dispatch’s Flare platform and DV-10 virus with CARsgen’s approved BCMA-targeting CAR T therapy zevor-cel in patients with epithelial solid tumors.\nThis alliance is significant because it seeks to adapt a multiple myeloma CAR T-cell therapy for solid tumors, an area where immunotherapies have historically faced major biological...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/will-dispatch-bio-car-t-solid-tumor-trial-shift-carsgen-ther","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/will-dispatch-bio-car-t-solid-tumor-trial-shift-carsgen-ther","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","LENZ","02171","BK4139","BK4230","CAR","BK1587","BK4022","BK4539","BK1574","BK1585","BK1161"],"gpt_icon":0},{"id":"2603915256","title":"Dianthus Therapeutics: Clinical Momentum, Pipeline Expansion, and Undervalued Catalysts Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2603915256","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603915256?lang=en_us&edition=fundamental","pubTime":"2026-01-14 17:36","pubTimestamp":1768383380,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on DNTH stock, giving a Buy rating on January 8. Myles Minter has given his ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dianthus-therapeutics-clinical-momentum-pipeline-expansion-and-undervalued-catalysts-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dianthus-therapeutics-clinical-momentum-pipeline-expansion-and-undervalued-catalysts-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2603667833","title":"Chordia Therapeutics Narrows Quarterly Loss but Forecasts Continued Full-Year Red Ink","url":"https://stock-news.laohu8.com/highlight/detail?id=2603667833","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603667833?lang=en_us&edition=fundamental","pubTime":"2026-01-14 14:57","pubTimestamp":1768373851,"startTime":"0","endTime":"0","summary":"Chordia Therapeutics Inc. ( ($JP:190A) ) has shared an announcement. Chordia Therapeutics reported non-consolidated results for the quarter ended 3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chordia-therapeutics-narrows-quarterly-loss-but-forecasts-continued-full-year-red-ink?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chordia-therapeutics-narrows-quarterly-loss-but-forecasts-continued-full-year-red-ink?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2603175669","title":"TFI Asset Management Reaffirms Their Buy Rating on CARsgen Therapeutics Holdings Ltd. (2171)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603175669","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603175669?lang=en_us&edition=fundamental","pubTime":"2026-01-14 13:05","pubTimestamp":1768367129,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from TFI Asset Management maintained a Buy rating on CARsgen Therapeutics Holdings Ltd., with a price target of HK$...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/tfi-asset-management-reaffirms-their-buy-rating-on-carsgen-therapeutics-holdings-ltd-2171-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/tfi-asset-management-reaffirms-their-buy-rating-on-carsgen-therapeutics-holdings-ltd-2171-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TFI","LENZ"],"gpt_icon":0},{"id":"2603865840","title":"BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603865840","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603865840?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:05","pubTimestamp":1768338300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Jan.  13, 2026  (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malign","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3218252/0/en/BridgeBio-Oncology-Therapeutics-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139","BK4007","BK4539","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.graphitebio.com","stockEarnings":[{"period":"1week","weight":0.1398},{"period":"1month","weight":0.0884},{"period":"3month","weight":-0.5404},{"period":"6month","weight":-0.4489},{"period":"1year","weight":-0.1686},{"period":"ytd","weight":0.1619}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.10333},{"month":2,"riseRate":0.5,"avgChangeRate":0.077415},{"month":3,"riseRate":0.25,"avgChangeRate":-0.098838},{"month":4,"riseRate":0.5,"avgChangeRate":-0.02248},{"month":5,"riseRate":0.25,"avgChangeRate":-0.134416},{"month":6,"riseRate":0.75,"avgChangeRate":0.05507},{"month":7,"riseRate":0.6,"avgChangeRate":0.05308},{"month":8,"riseRate":0.4,"avgChangeRate":0.016536},{"month":9,"riseRate":0.6,"avgChangeRate":0.026875},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}